Floatz logo

Odronextamab

B-Cell Non-Hodgkin Lymphoma (B-NHL)

University of BirminghamPhase 3Active
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

316 Active assets in the B-Cell Non-Hodgkin Lymphoma (B-NHL) cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB
CARMUSTINE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB

View all 50 →

Same molecule, other indications

Odronextamab is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
follicular lymphomaDormant
B
Indicative ·
62 / 100
View asset →
high grade B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →